Clinical and technical outcome
| n=10 | |
| mRS score at follow-up, median (IQR) | 1 (0–1) |
| Post-procedure degree of stenosis (%) according to WASID Study Group, median (IQR) | 50 (45–53%)%) |
| Mortality rate during follow-up*, n | 0 |
| Peri- and post-procedure clinical ischemic events, n | 0 |
| Restenosis during follow-up*, n | 0 |
| Intracranial clinical complications†, n | 0 |
| Technical failure rate, n | 0 |
*Median follow-up of 3 months (IQR 2–3).
†We observed one asymptomatic snow-plough effect.
mRS, modified Rankin Scale; WASID, Warfarin-Aspirin Symptomatic Intracranial Disease Trial.